Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas
Status:
Completed
Trial end date:
2003-08-01
Target enrollment:
Participant gender:
Summary
Patients with Zollinger-Ellison Syndrome suffer from ulcers of the upper gastrointestinal
tract, higher than normal levels of gastric acid, and tumors of the pancreas known as
non-beta islet cell tumors.
Prior to the use of drugs to cure the ulcers, patients typically died due to severe ulcers.
Because of such effective drugs to treat the ulcers it is more common to see patients dying
due to the pancreatic tumors.
The study will observe patients suffering from Zollinger-Ellison Syndrome and non-beta islet
cell tumors and determine the effectiveness of combined chemotherapy with streptozotocin,
5-fluorouracil, and doxorubicin.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)